Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Victoria Bejarano"'
Publikováno v:
Lewis & Clark Law Review. 2022, Vol. 26 Issue 1, p241-274. 34p.
Autor:
Sarah L, Mackie, Bhaskar, Dasgupta, Lesley, Hordon, Andrew, Gough, Michael, Green, Jane, Hollywood, Shouma, Dutta, Victoria, Bejarano, Stephen, Jarrett, Ann W, Morgan, Colin T, Pease, Richard, Watts
Publikováno v:
Rheumatology. 50:2014-2022
Objectives. To determine whether ischaemic manifestations of GCA are associated with pre-existing hypertension, atherosclerosis or area-level socio-economic deprivation. Methods. We conducted an observational study of rheumatologist/ophthalmologist-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da3bd8b7fd25430f3d08cc0eb3ac1280
https://doi.org/10.1093/rheumatology/ker265
https://doi.org/10.1093/rheumatology/ker265
Autor:
Victoria Bejarano, Lesley D. Hordon, Philip G. Conaghan, Hartmut Kupper, Stephen J. Jarrett, Andrew Gough, Anne-Maree Keenan, Mark A. Quinn, Michael J. Green, Ade Adebajo, David Walker, Richard Melsom, Paul Emery, Dennis McGonagle, Richard Reece, Kristina Unnebrink, S. M. Doherty
Publikováno v:
Arthritis & Rheumatism. 59:1467-1474
Objective To compare work disability and job loss in early rheumatoid arthritis (RA) patients receiving adalimumab plus methotrexate (adalimumab + MTX) versus MTX alone. Methods In this multicenter, randomized, controlled trial, patients with RA for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edccfa71b7437125e6e3f47bcb7a0f96
https://doi.org/10.1002/art.24106
https://doi.org/10.1002/art.24106
Autor:
K Henshaw, Mark A. Quinn, Maya H Buch, G Cunnane, Paul Emery, Victoria Bejarano, John D. Isaacs, Richard Reece, Sarah J. Bingham, Anne English
Publikováno v:
Rheumatology. 47:1469-1475
OBJECTIVES Clinical response to TNF-alpha blockade in the treatment of RA is heterogeneous. The study aims were to determine whether pre-treatment synovial cytokine expression predicted infliximab response and whether synovial changes after therapy c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffaca9d96dfcc64e9421eb2c523f6ae
https://doi.org/10.1093/rheumatology/ken261
https://doi.org/10.1093/rheumatology/ken261
Autor:
Maya H Buch, Dennis McGonagle, Sarah J. Bingham, J White, Paul Emery, Yohei Seto, Victoria Bejarano
Publikováno v:
Arthritis & Rheumatism. 50:725-728
Objective. In patients with rheumatoid arthritis (RA) treated with tumor necrosis factor α (TNFα)– blocking therapy, there is heterogeneity of response. This raises the possibility that in certain circumstances, cytokines such as interleukin-1 (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59218514c0a0711c985f02353f61eec5
https://doi.org/10.1002/art.20115
https://doi.org/10.1002/art.20115
Publikováno v:
Annals of the Rheumatic Diseases. 68:761-763
Whereas the optimum therapy for early rheumatoid arthritis (RA) has not been established, there is still interest in combination therapy with existing disease-modifying antirheumatic drugs, due to the cost and toxicity of biological agents. We previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cabeed4cef96a849947594d2f892c6a
https://doi.org/10.1136/ard.2008.091553
https://doi.org/10.1136/ard.2008.091553
Autor:
Victoria Bejarano, Andrew K. Brown, Philip G. Conaghan, Elizabeth M A Hensor, Glenn Haugeberg, Paul Emery, Michael J. Green, Maya H Buch
Publikováno v:
Arthritis careresearch. 64(1)
Objective To ascertain whether bone mineral density loss during the first year of treatment for early rheumatoid arthritis (RA) as assessed by dual x-ray absorptiometry (DXA) is associated with long-term function, quality of life, and radiographic pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b98b18ac656fb09e60d8f68402d607
https://pubmed.ncbi.nlm.nih.gov/21770041
https://pubmed.ncbi.nlm.nih.gov/21770041
Publikováno v:
Rheumatology (Oxford, England). 49(10)
OBJECTIVE To ascertain whether a 1-year remission induction therapy with an infliximab-MTX (INF-MTX) combination in patients with early RA provided sustained benefit after INF cessation compared with conventional treatment. METHODS Twenty patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4e953af310dfddb615bd5dbd6d054d
https://pubmed.ncbi.nlm.nih.gov/20595536
https://pubmed.ncbi.nlm.nih.gov/20595536
Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept
Autor:
Richard Reece, Mark A. Quinn, Victoria Bejarano, Paul Emery, Maya H Buch, J White, Domini Bryer, Sarah J. Bingham
Publikováno v:
Arthritis and rheumatism. 57(3)
Objective The role of alternative tumor necrosis factor (TNF) antagonist therapies in the context of failure of initial TNF antagonist therapy in patients with rheumatoid arthritis (RA) has yet to be clearly defined. The goal of this study was to det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e99df064b9bc6465c3710028de13077
https://pubmed.ncbi.nlm.nih.gov/17394231
https://pubmed.ncbi.nlm.nih.gov/17394231
Autor:
Victoria Bejarano, Paul Emery, Sarah J. Bingham, J White, Domini Bryer, Yohei Seto, Maya H Buch
Publikováno v:
Arthritis and rheumatism. 52(1)
Objective Nonresponse to anti–tumor necrosis factor α in patients with rheumatoid arthritis (RA) is poorly understood. The aims of this study were to define nonresponse patterns using infliximab and C-reactive protein (CRP) profiles, to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32f5d5198b4561c5798aceed016dbe94
https://pubmed.ncbi.nlm.nih.gov/15641046
https://pubmed.ncbi.nlm.nih.gov/15641046